STEL Technologies was founded by researchers at the University of Michigan. We are committed to advancing the field of tissue engineering with our technology and helping revolutionize the treatment of soft tissue injuries.
The foundational science behind our work has been supported by grants from the National Science Foundation, National Institutes of Health and Advanced Regenerative Manufacturing Institute.
Today, many surgical repairs for tears of the anterior cruciate ligament (ACL) use tendon – most commonly the patellar tendon – in place of the ACL (a ligament). This is mismatch in tissue types creates a system that is not designed to perform in the way the body expects it, resulting in strain and increased risk of re-injury. STEL aims to revolutionize soft tissue repair with an engineered, biological fix.
STEL is a biotech company focused on the development and commercialization of solutions for soft tissue repair. We are creating biological solutions for patients with knee and shoulder injuries. Our cell-generated tissue grafts for ACL and Rotator Cuff aim to encourage the body’s own biological healing process and restore normal biomechanics.
ACL tears affect hundreds of thousands of Americans, sidelining athletes and contributing to osteoarthritis. We are working on technology to give physicians new tools to repair ACLs.
ROTATOR CUFF GRAFT
Shoulder injuries are one of the most common orthopedic complaints among older adults. Surgery with today's technology has a high failure rate. Our work focused on giving surgeons tools to help the body repair the rotator cuff.
STEL has developed a fully-closed, proprietary tissue bioreactor that allows for safe, scalable development of cell-based therapies.